X4 Pharmaceuticals Inc.

06/27/2024 | Press release | Distributed by Public on 06/27/2024 04:31

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN[...]